Wrinkle remover Revance files for $86 million IPO

01/06/2014

Revance Therapeutics Inc., a developer of next-generation versions of skin wrinkle eraser Botox, is seeking $86.25 million in an initial public offering.
Register

We're glad to see you're enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free